Targeted therapy in multiple myeloma

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Multiple myeloma (MM) is a fatal blood cancer.
• MM cells interact with the bone marrow microenvironment, leading to drug resistance, growth, and survival.
• Recent biological insights enable novel therapies targeting MM cells and their microenvironment.

Purpose of the Study:

• To review recent advances in MM biology.
• To summarize novel therapeutic agents, their mechanisms of action, and clinical efficacy.

Main Methods:

• Literature review of recent advances in multiple myeloma.
• Summary of novel therapeutic agents in clinical trials.

Main Results:

• Thalidomide is established for initial and salvage treatment.
• Bortezomib is under investigation in various settings.
• Other agents like arsenic trioxide and VEGF inhibitors show potential in relapsed/refractory MM.
• Novel agents targeting drug resistance mechanisms (e.g., Bcl-2 antisense) are being developed.
• Gene expression studies provide insights into therapeutic mechanisms.

Conclusions:

• Future MM patients will have expanded therapeutic options.
• Identifying patient subgroups benefiting from specific therapies is crucial.
• Combining and integrating biologically based therapies into MM management is the next challenge.